CRISPR & Cas Genes Market Size Will Attain USD 8.96 Bn By 2030

The global CRISPR & Cas genes market size accounted for USD 2.55 billion in 2022 and is projected to hit around USD 8.96 billion by 2030 with a remarkable CAGR of 17.03% between 2022 and 2030.


The demand for the use of CRISPR gene editing technology has significantly increased recently. By enabling accurate and effective genetic modification of various eukaryotic genomes, including human genomes, Cas9, the CRISPR RNA-guided nuclease, has revolutionized genetics and driven the market. The expansion of human germline altering, the progress of technology, and the development of tools for descriptive and analytical plant genome formatting are all expected to contribute to the growth of the gene market over the course of the forecast period.


Download a Free Sample Copy of this Report@


Market Growth

The widespread use of CRISPR Cas genes in the therapy of disease is a result of the prevalence of genetic defects in humans. Additionally, CRISPR-Cas technologies have been widely used in genome editing in molecular biology laboratories all over the world because of their straightforward design, low cost, high efficiency, great repeatability, and short cycle, which is expected to propel market growth. Additionally, CAS and CRISPR gene technology studies and studies by many experts around the world are intensifying, driving revenue growth in this market sector. In addition, many organizations are focusing right now on launching cutting-edge clinical studies for the Cas and CRISPR genes for cancer treatment.


Regional Analysis

The global CRISPR and Cas Genes Market is divided into North America, Europe, Asia Pacific, and the Rest of the World based on the regional analysis. By accounting for 38.4% of market revenue for CRISPR and Cas Genes in 2020, North America held the greatest market share. The region's supremacy has been considerably aided by the growing biopharmaceutical R&D as well as the active involvement of various pharmaceutical companies in the development of novel medications using genome editing methods. Over the course of the prediction period, Asia Pacific is anticipated to experience the strongest growth. China holds a significant position in the global CRISPR business and is gradually learning how to use genome editing to improve pharmaceuticals. Numerous CRISPR-based clinical studies have been established, mainly for the treatment of cancer.


CRISPR & Cas Genes Market Report Scope

Report Coverage


Market Size In 2022

US$ 2.55 Billion

Market Size By 2030

US$ 8.96 Billion

Growth Rate From 2022 to 2030

CAGR of 17.03%

Base Year


Forecast Period

2022 to 2030

Segments Covered          

  • By Product & Service
  • By Application
  • By End-use Outlook

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa 



Ask Here for Customization@


Market Dynamics


Market Drivers

Global market expansion is driven by significant investment raised by the major market players to support the development and enhancement of the CRISPR Cas9 genes-editing technique. For instance, in January 2020, Mammoth Biosciences secured over USD 45 million in strategic funding, boosting its total budget to over USD 70 million. This money will be utilized to expand its CRISPR genes-driven diagnostics capabilities. The focus on developing novel therapies as a result of the increasing prevalence of various genetic diseases and cancer is a major factor anticipated to propel the growth of the CRISPR and Cas genes market in the years to come. Demand in the target market is anticipated to increase in the coming years as a result of additional high-tech developments in the CRISPR industry.


Market Drivers

It is anticipated that the high expenses associated with using CRISPR genes will somewhat restrain global market expansion. Additionally, it is anticipated that during the course of the forecast period, growth in the global CRISPR & Cas genes market will be restrained by ethical concerns about human genome editing.


Report Highlight 


Application Insight

Biomedical application accounted for more than 90% of the market in 2021 across the various application segments examined in this research study. This enormous portion of revenue is due to the increased use of CRISPR in biomedical research. The number of studies using this technique to modify the genomes of human somatic cells and induced pluripotent stem cells has significantly increased.

Product Insight

In 2021, the product sector dominated the global market in terms of revenue, holding more than 75% of the market. The development of synthetic enzymes and the combination of other enzymes, such as Cas12a and Cas9, are some of the key elements promoting this proliferation. This is because modified enzymes offer greater experiment flexibility and are now being used more frequently by scientists.

End-User Insight

The largest portion of the market's overall revenue was accounted for by the category of biotechnology and pharmaceutical firms. Pharmaceutical start-ups are stronger than ever to advance goods employing CRISPR-mediated gene-editing techniques thanks to the impending clinical uses of CRISPR-Cas9. The market has also seen mergers between emerging and developing businesses with CRISPR-based services and product ranges.


Recent Development 

  • In August 2022, By providing arrayed CRISPR-edited cells for use directly in functional screening assays, Synthego's engineered cell libraries, a state-of-the-art service, increased access to CRISPR technology.


  • In January 2020, 45 million USD was raised by Mammoth Biosciences to create next-generation CRISPR products for medicinal and diagnostic uses.


Market Key Players:


  • Caribou Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cellectis
  • AstraZeneca
  • Editas Medicine, Inc.
  • Addgene
  • Egenesis
  • Horizon Discovery Group Plc
  • Intellia Therapeutics, Inc.
  • Genscrip
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • New England BioLabs
  • Takara Bio, Inc.


Market Segmentation

By Product & Service

  • By Service
    • Microbial Gene Editing
    • Cell Line Engineering
    • gRNA Design
    • DNA Synthesis
  • By Product
    • Design Tool
    • Kits & Enzymes
    • Libraries
    • Antibodies
    • Others

By Application

  • Agricultural
  • Biomedical
    • Functional Genomics
    • Genome Engineering
    • Disease Model Studies
    • Epigenetics
    • Others

End-use Outlook

    • Contract Research Organizations (CROs),
    • Academics & Government Research Institutes
    • Biotechnology & Pharmaceutical Companies

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Click Here to View Full Report Table of Contents

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333

Back to news